Income Taxes	3 Months Ended
Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company evaluates its deferred tax assets quarterly to determine if valuation allowances are required. In assessing the realizability of deferred tax assets, the Company considers both positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company had a valuation allowance of $0.1 million against its deferred tax assets related to certain state tax jurisdictions as of March 31, 2017 and December 31, 2016. To the extent the Company generates future tax net operating losses, the Company may be required to increase the valuation allowance on deferred tax assets, which may unfavorably impact the effective tax rate. The Company has no material uncertain tax positions as of March 31, 2017 and December 31, 2016. For the three months ended March 31, 2017, the Company’s effective tax rate was 20.6%, which varied from the federal statutory rate of 35% primarily due to excess tax windfall benefits from stock compensation of $0.8 million offset by state income tax expense. For the three months ended March 31, 2016, the effective tax rate was 36.8%, which varied from the federal statutory rate of 35% primarily due to state taxes and non-deductible costs related to the merger of BMHC and SBS (the “Merger”).

Income Taxes

3 Months Ended

Mar. 31, 2017

The Company evaluates its deferred tax assets quarterly to determine if valuation allowances are required. In assessing the realizability of deferred tax assets, the Company considers both positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company had a valuation allowance of $0.1 million against its deferred tax assets related to certain state tax jurisdictions as of March 31, 2017 and December 31, 2016. To the extent the Company generates future tax net operating losses, the Company may be required to increase the valuation allowance on deferred tax assets, which may unfavorably impact the effective tax rate.

The Company has no material uncertain tax positions as of March 31, 2017 and December 31, 2016.

For the three months ended March 31, 2017, the Company’s effective tax rate was 20.6%, which varied from the federal statutory rate of 35% primarily due to excess tax windfall benefits from stock compensation of $0.8 million offset by state income tax expense. For the three months ended March 31, 2016, the effective tax rate was 36.8%, which varied from the federal statutory rate of 35% primarily due to state taxes and non-deductible costs related to the merger of BMHC and SBS (the “Merger”).